CRISPR Will Likely Not Solve Bird Flu
By Carol Cardona and Michelle Kromm,
Scientific American
| 03. 11. 2024
Recently, a group of scientists announced a breakthrough approach to combat Highly Pathogenic Avian Influenza (bird flu or avian flu), a severe illness of birds that has killed millions of chickens worldwide since it emerged in 1996 and continues to devastate bird populations. This disease has quickly become a potential threat to human health and has affected both food prices and availability.
Their approach uses a gene-editing technique called CRISPR/Cas9. In general, this method changes defined segments of an animal’s genetic code to functionally alter what that code does. In this case, CRISPR was used to alter chickens’ genetic code to make chickens more resistant to avian flu. While this was a fascinating use of the technology, any time scientific innovation affects the food we eat, it becomes a sensitive issue. On top of philosophical concerns regarding the use of CRISPR within our food supply, we think there are too many unpredictable outcomes related to combating avian influenza with CRISPR-modified chickens to expect this technology will be a solution to this destructive disease.
While CRISPR has created almost infinite opportunities...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...